Another clinical trial including 44 overweight or obese adults with T1DM found that adding liraglutide as an add-on therapy to insulin was associated with a reduction in HbA1c from baseline by 0.5%, total daily insulin by 16%, and mean body weight by 6.3 kg compared with a placebo group. This evidence concerns the gene INS and type 1 diabetes mellitus.